Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Multicentric Single Arm Phase II Study Evaluating the Efficacy of Association of Tucatinib, Capecitabine and Intra-CSF Trastuzumab in HER2 Amplified Breast Cancer Patients with Leptomeningeal Metastases

Next Previous
Search
Trial Profile

Multicentric Single Arm Phase II Study Evaluating the Efficacy of Association of Tucatinib, Capecitabine and Intra-CSF Trastuzumab in HER2 Amplified Breast Cancer Patients with Leptomeningeal Metastases

Status: Recruiting
Phase of Trial: Phase II

Latest Information Update: 06 Sep 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Capecitabine (Primary) ; Trastuzumab (Primary) ; Tucatinib (Primary)
  • Indications Advanced breast cancer; HER2 positive breast cancer; Meningeal carcinomatosis
  • Focus Therapeutic Use
  • Acronyms ETIC-LM
  • Sponsors Seagen

    • Most Recent Events

    • 02 Feb 2024 Planned End Date changed from 1 May 2027 to 1 Jun 2027.
    • 02 Feb 2024 Planned primary completion date changed from 1 Nov 2026 to 1 Dec 2026.
    • 02 Feb 2024 Status changed from not yet recruiting to recruiting.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top